Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities-Reference-Cited by-同舟云学术

Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities

Published:2010-11-09 Issue:1 Volume:129 Page:151-159
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Dillner Lena,Kemetli Levent,Elfgren Kristina,Bogdanovic Gordana,Andersson Pia,Carlsten-Thor Agneta,Andersson Sonia,Persson Elisabeth,Rylander Eva,Grillner Lena,Dillner Joakim,Törnberg Sven

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Cervix

2. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop;Kurman;JAMA,1994

3. HPV testing: is it useful in triage of minor Pap abnormalities?;Cox;J Fam Pract,1998

4. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document;Arbyn;Ann Oncol,2010

5. Risk of cervical cancer associated with mild dyskaryosis;Robertson;BMJ,1988

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of triage strategies for atypical squamous cells of undetermined significance among young women;International Journal of Gynecology & Obstetrics;2024-09-13

2. Atypical glandular cells and development of cervical cancer: Population‐based cohort study;International Journal of Cancer;2022-08-27

3. Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial;PLOS Medicine;2021-08-23

4. Associations of treated and untreated human papillomavirus infection with preterm delivery and neonatal mortality: A Swedish population-based study;PLOS Medicine;2021-05-10

5. Comparison of immediate colposcopy, repeat conventional cytology and high‐risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The ASCUS‐COL trial;International Journal of Cancer;2020-10-24